ASX - By Stock
|
IIQ |
Re:
Ann: Lung Cancer Study Results
|
|
0xbadc0ded
|
39 |
24K |
4 |
15/05/17 |
15/05/17 |
ASX - By Stock
|
39
|
24K
|
4
|
|
ASX - By Stock
|
FMG |
Re:
Iron ore price
|
|
0xbadc0ded
|
52K |
28M |
1 |
15/05/17 |
15/05/17 |
ASX - By Stock
|
52K
|
28M
|
1
|
|
ASX - By Stock
|
FMG |
Re:
Iron ore price
|
|
0xbadc0ded
|
52K |
28M |
4 |
15/05/17 |
15/05/17 |
ASX - By Stock
|
52K
|
28M
|
4
|
|
ASX - By Stock
|
FMG |
Re:
Iron ore price
|
|
0xbadc0ded
|
52K |
28M |
4 |
15/05/17 |
15/05/17 |
ASX - By Stock
|
52K
|
28M
|
4
|
|
ASX - By Stock
|
FMG |
Re:
Iron ore price
|
|
0xbadc0ded
|
52K |
28M |
3 |
14/05/17 |
14/05/17 |
ASX - By Stock
|
52K
|
28M
|
3
|
|
ASX - By Stock
|
FMG |
Re:
Iron ore price
|
|
0xbadc0ded
|
52K |
28M |
0 |
13/05/17 |
13/05/17 |
ASX - By Stock
|
52K
|
28M
|
0
|
|
ASX - By Stock
|
AVR |
Re:
"Take a Closer Look"
|
|
0xbadc0ded
|
1.2K |
445K |
5 |
13/05/17 |
13/05/17 |
ASX - By Stock
|
1.2K
|
445K
|
5
|
|
ASX - By Stock
|
AVR |
Re:
"Take a Closer Look"
|
|
0xbadc0ded
|
1.2K |
445K |
1 |
12/05/17 |
12/05/17 |
ASX - By Stock
|
1.2K
|
445K
|
1
|
|
ASX - By Stock
|
AVR |
Re:
"Take a Closer Look"
|
|
0xbadc0ded
|
1.2K |
445K |
4 |
12/05/17 |
12/05/17 |
ASX - By Stock
|
1.2K
|
445K
|
4
|
|
ASX - By Stock
|
AVR |
Re:
"Take a Closer Look"
|
|
0xbadc0ded
|
1.2K |
445K |
3 |
12/05/17 |
12/05/17 |
ASX - By Stock
|
1.2K
|
445K
|
3
|
|
ASX - By Stock
|
FMG |
Re:
Iron ore price
|
|
0xbadc0ded
|
52K |
28M |
0 |
11/05/17 |
11/05/17 |
ASX - By Stock
|
52K
|
28M
|
0
|
|
ASX - By Stock
|
FMG |
Re:
Iron ore price
|
|
0xbadc0ded
|
52K |
28M |
4 |
11/05/17 |
11/05/17 |
ASX - By Stock
|
52K
|
28M
|
4
|
|
ASX - By Stock
|
FMG |
Re:
Iron ore price
|
|
0xbadc0ded
|
52K |
28M |
3 |
11/05/17 |
11/05/17 |
ASX - By Stock
|
52K
|
28M
|
3
|
|
ASX - By Stock
|
FMG |
Re:
Iron ore price
|
|
0xbadc0ded
|
52K |
28M |
2 |
10/05/17 |
10/05/17 |
ASX - By Stock
|
52K
|
28M
|
2
|
|
ASX - By Stock
|
FMG |
Re:
Iron ore price
|
|
0xbadc0ded
|
52K |
28M |
4 |
09/05/17 |
09/05/17 |
ASX - By Stock
|
52K
|
28M
|
4
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Admedus Releases Results of HSV-2 Phase IIa Study
|
|
0xbadc0ded
|
350 |
143K |
13 |
06/05/17 |
06/05/17 |
ASX - By Stock
|
350
|
143K
|
13
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Admedus Releases Results of HSV-2 Phase IIa Study
|
|
0xbadc0ded
|
350 |
143K |
4 |
05/05/17 |
05/05/17 |
ASX - By Stock
|
350
|
143K
|
4
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Admedus Releases Results of HSV-2 Phase IIa Study
|
|
0xbadc0ded
|
350 |
143K |
6 |
05/05/17 |
05/05/17 |
ASX - By Stock
|
350
|
143K
|
6
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Admedus Releases Results of HSV-2 Phase IIa Study
|
|
0xbadc0ded
|
350 |
143K |
3 |
05/05/17 |
05/05/17 |
ASX - By Stock
|
350
|
143K
|
3
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Admedus Releases Results of HSV-2 Phase IIa Study
|
|
0xbadc0ded
|
350 |
143K |
2 |
05/05/17 |
05/05/17 |
ASX - By Stock
|
350
|
143K
|
2
|
|
ASX - By Stock
|
FMG |
Re:
fmg and fe
|
|
0xbadc0ded
|
1.8K |
560K |
1 |
05/05/17 |
05/05/17 |
ASX - By Stock
|
1.8K
|
560K
|
1
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Admedus Releases Results of HSV-2 Phase IIa Study
|
|
0xbadc0ded
|
350 |
143K |
1 |
05/05/17 |
05/05/17 |
ASX - By Stock
|
350
|
143K
|
1
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Admedus Releases Results of HSV-2 Phase IIa Study
|
|
0xbadc0ded
|
350 |
143K |
6 |
04/05/17 |
04/05/17 |
ASX - By Stock
|
350
|
143K
|
6
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Admedus Releases Results of HSV-2 Phase IIa Study
|
|
0xbadc0ded
|
350 |
143K |
1 |
04/05/17 |
04/05/17 |
ASX - By Stock
|
350
|
143K
|
1
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Admedus Releases Results of HSV-2 Phase IIa Study
|
|
0xbadc0ded
|
350 |
143K |
5 |
04/05/17 |
04/05/17 |
ASX - By Stock
|
350
|
143K
|
5
|
|
ASX - By Stock
|
FMG |
Re:
Iron ore price
|
|
0xbadc0ded
|
52K |
28M |
3 |
04/05/17 |
04/05/17 |
ASX - By Stock
|
52K
|
28M
|
3
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Admedus Releases Results of HSV-2 Phase IIa Study
|
|
0xbadc0ded
|
350 |
143K |
0 |
04/05/17 |
04/05/17 |
ASX - By Stock
|
350
|
143K
|
0
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Investor Webinar Presentation - HSV-2 Phase IIa Results
|
|
0xbadc0ded
|
2 |
1.3K |
3 |
04/05/17 |
04/05/17 |
ASX - By Stock
|
2
|
1.3K
|
3
|
|
ASX - By Stock
|
FMG |
Re:
Iron ore price
|
|
0xbadc0ded
|
52K |
28M |
5 |
03/05/17 |
03/05/17 |
ASX - By Stock
|
52K
|
28M
|
5
|
|
ASX - By Stock
|
AVR |
Re:
Ann: HSV-2 Phase IIa Results Investor Webinar
|
|
0xbadc0ded
|
296 |
158K |
0 |
03/05/17 |
03/05/17 |
ASX - By Stock
|
296
|
158K
|
0
|
|
ASX - By Stock
|
AVR |
Re:
Ann: HSV-2 Phase IIa Results Investor Webinar
|
|
0xbadc0ded
|
296 |
158K |
3 |
02/05/17 |
02/05/17 |
ASX - By Stock
|
296
|
158K
|
3
|
|
ASX - By Stock
|
AVR |
Re:
Ann: HSV-2 Phase IIa Results Investor Webinar
|
|
0xbadc0ded
|
296 |
158K |
2 |
02/05/17 |
02/05/17 |
ASX - By Stock
|
296
|
158K
|
2
|
|
ASX - By Stock
|
AVR |
Re:
Ann: HSV-2 Phase IIa Results Investor Webinar
|
|
0xbadc0ded
|
296 |
158K |
1 |
02/05/17 |
02/05/17 |
ASX - By Stock
|
296
|
158K
|
1
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Admedus Receives FDA Clearance for CardioCel 3D
|
|
0xbadc0ded
|
134 |
51K |
6 |
02/05/17 |
02/05/17 |
ASX - By Stock
|
134
|
51K
|
6
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Admedus Receives FDA Clearance for CardioCel 3D
|
|
0xbadc0ded
|
134 |
51K |
0 |
02/05/17 |
02/05/17 |
ASX - By Stock
|
134
|
51K
|
0
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Admedus Receives FDA Clearance for CardioCel 3D
|
|
0xbadc0ded
|
134 |
51K |
5 |
02/05/17 |
02/05/17 |
ASX - By Stock
|
134
|
51K
|
5
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Admedus Receives FDA Clearance for CardioCel 3D
|
|
0xbadc0ded
|
134 |
51K |
1 |
02/05/17 |
02/05/17 |
ASX - By Stock
|
134
|
51K
|
1
|
|
ASX - By Stock
|
AVR |
Re:
Ann: HSV-2 Phase IIa Results Investor Webinar
|
|
0xbadc0ded
|
296 |
158K |
0 |
01/05/17 |
01/05/17 |
ASX - By Stock
|
296
|
158K
|
0
|
|
ASX - By Stock
|
AVR |
Re:
Ann: HSV-2 Phase IIa Results Investor Webinar
|
|
0xbadc0ded
|
296 |
158K |
1 |
01/05/17 |
01/05/17 |
ASX - By Stock
|
296
|
158K
|
1
|
|
ASX - By Stock
|
AVR |
Re:
Ann: HSV-2 Phase IIa Results Investor Webinar
|
|
0xbadc0ded
|
296 |
158K |
0 |
01/05/17 |
01/05/17 |
ASX - By Stock
|
296
|
158K
|
0
|
|
ASX - By Stock
|
AVR |
Re:
Ann: HSV-2 Phase IIa Results Investor Webinar
|
|
0xbadc0ded
|
296 |
158K |
0 |
01/05/17 |
01/05/17 |
ASX - By Stock
|
296
|
158K
|
0
|
|
ASX - By Stock
|
AVR |
Re:
Ann: HSV-2 Phase IIa Results Investor Webinar
|
|
0xbadc0ded
|
296 |
158K |
0 |
01/05/17 |
01/05/17 |
ASX - By Stock
|
296
|
158K
|
0
|
|
ASX - By Stock
|
AVR |
Re:
Ann: HSV-2 Phase IIa Results Investor Webinar
|
|
0xbadc0ded
|
296 |
158K |
0 |
01/05/17 |
01/05/17 |
ASX - By Stock
|
296
|
158K
|
0
|
|
ASX - By Stock
|
AVR |
Re:
Ann: HSV-2 Phase IIa Results Investor Webinar
|
|
0xbadc0ded
|
296 |
158K |
0 |
01/05/17 |
01/05/17 |
ASX - By Stock
|
296
|
158K
|
0
|
|
ASX - By Stock
|
AVR |
Re:
Ann: HSV-2 Phase IIa Results Investor Webinar
|
|
0xbadc0ded
|
296 |
158K |
0 |
01/05/17 |
01/05/17 |
ASX - By Stock
|
296
|
158K
|
0
|
|
ASX - By Stock
|
AVR |
Re:
Ann: HSV-2 Phase IIa Results Investor Webinar
|
|
0xbadc0ded
|
296 |
158K |
1 |
01/05/17 |
01/05/17 |
ASX - By Stock
|
296
|
158K
|
1
|
|
ASX - By Stock
|
AVR |
Re:
Ann: HSV-2 Phase IIa Results Investor Webinar
|
|
0xbadc0ded
|
296 |
158K |
0 |
01/05/17 |
01/05/17 |
ASX - By Stock
|
296
|
158K
|
0
|
|
ASX - By Stock
|
AVR |
Re:
Ann: HSV-2 Phase IIa Results Investor Webinar
|
|
0xbadc0ded
|
296 |
158K |
1 |
01/05/17 |
01/05/17 |
ASX - By Stock
|
296
|
158K
|
1
|
|
ASX - By Stock
|
AVR |
Re:
Ann: HSV-2 Phase IIa Results Investor Webinar
|
|
0xbadc0ded
|
296 |
158K |
0 |
01/05/17 |
01/05/17 |
ASX - By Stock
|
296
|
158K
|
0
|
|
ASX - By Stock
|
AVR |
Re:
Ann: HSV-2 Phase IIa Results Investor Webinar
|
|
0xbadc0ded
|
296 |
158K |
2 |
01/05/17 |
01/05/17 |
ASX - By Stock
|
296
|
158K
|
2
|
|